Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study) (151)
Monday, April 27April 14, 2020Free AccessAlemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study) (151)Ann D. Bass, Raed Alroughani, Simon Broadley, Giancarlo Comi, Yang Mao-Draayer, Hans-Peter Hartung, Eva Kubala Havrdova, … Show All … , Ho Jin Kim, Kunio Nakamura, Carlos Navas, Alex Rovira, Krzysztof W. Selmaj, Patrick Vermersch, Sibyl Wray, Zia Choudhry, Nadia Daizadeh, Salman Afsar, and Barry A. Singer Show FewerAuthors Info & AffiliationsApril 14, 2020 issue94 (15_supplement)https://doi.org/10.1212/WNL.94.15_supplement.151 Letters to the Editor
